Drug Trial Radar · NCT07698600
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Aug 4, 2026
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and how it affects the amount of virus in the body.
Conditions
- HIV -1 Infection
Interventions
BNT168Biological
Intramuscular injection to be applied in the deltoid muscle, using the same non-dominant arm for all IMP injections
PlaceboOther
Isotonic sodium chloride (NaCl) solution (0.9%). Intramuscular injection to be applied in the deltoid muscle, using the same non-dominant arm for all IMP injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of at least one adverse eventTime frame: From dosing through 28 days after each IMP dose
- Occurrence of at least one serious adverse eventTime frame: From Dose 1 through the end of study (up to 12 months)
- Occurrence of at least one adverse event of special interestTime frame: From Dose 1 through the end of study (up to 12 months)
- Occurrence of at least one solicited local reaction (pain, erythema/redness, swelling) at the IMP injection siteTime frame: Up to 7 days after each IMP dose
- Occurrence of at least one solicited systemic event (vomiting, diarrhea, headache, fatigue/tiredness, myalgia/muscle pain, fever)Time frame: Up to 7 days after each IMP dose
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri · Not yet recruiting
AMR Clinical Knoxville
Knoxville, Tennessee · Recruiting
The Crofoot Research Center
Houston, Texas · Recruiting
Perinatal HIV Research Unit (PHRU)
Johannesburg, South Africa · Recruiting
Wits RHI - Shandukani Research
Johannesburg, South Africa · Recruiting
Clinical HIV Research Unit (CHRU)
Johannesburg, South Africa · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.